Cancer is not just one disease, but a large group of almost one hundred diseases. Its two main characteristics are uncontrolled growth of the cells in the human body and the ability of these cells to migrate from the original site and spread to distant sites. If the spread is not controlled, cancer can result in death.
Deadly skin cancer cases hit record high – During the last 30 years malignant melanoma rates have more than quadrupled. – The number of people diagnosed with the deadliest form of skin cancer has crashed through the 10,000 barrier after an alarming rise in new cases, according to the latest Cancer Research UK figures.
African-American women with advanced breast cancer often forego vital treatment – A new study finds that nearly one in four African American women with late stage breast cancer refused chemotherapy and radiation therapy, potentially life saving therapies.
Patients with Down syndrome have a reduced risk for cancer focused on endostatin, an anti-angiogenic compound made by the body. – Most cancers are rare in people with Down syndrome, whose overall cancer mortality is below 10 percent of that in the general population.
Quick test for prostate cancer – A new 3-minute test could help in diagnosing prostate cancer, the most common cancer in men in the UK, according to scientists. – A new 3-minute test could help in diagnosing prostate cancer, the most common cancer in men in the UK, according to scientists. Researchers have developed the test by using light energy to measure the level of citrate in fluid samples from the prostate gland.
Researchers make discovery in colon cancer prevention — Individuals who have low levels of ‘Celebrex gene’ are resistant to Celebrex treatment for colon tumor prevention. – A new study finds that individuals who have low expression of the “Celebrex gene,” 15-PGDH, are actually resistant to Celebrex treatment when used to prevent colon cancer.
HRT-breast cancer risk stays same, regardless of family history – HRT conveys no greater breast cancer risk to women with, versus without, a first-degree family history of breast cancer. – The risk of developing breast cancer due to taking hormone replacement therapy appears to be the same for women with a family history of the disease and without a family history, a University of Rochester Medical Center study concluded.
Low-income breast cancer patients skipping hormonal therapy, increasing their risks – Many low-income women are failing to take the hormonal therapy prescribed as part of their breast cancer treatment, possibly lowering their survival rates, according to a study led by a researcher in the Duke Comprehensive Cancer Center.
Ginger quells cancer patients’ nausea from chemotherapy – People with cancer can reduce post-chemotherapy nausea by 40 percent by using ginger supplements, along with standard anti-vomiting drugs, before undergoing treatment, according to scientists at the University of Rochester Medical Center.
City-dwellers have higher risk of late-stage cancer than rural residents – People who live in urban areas are more likely to develop late-stage cancer than those who live in suburban and rural areas. That is the conclusion of a new study published in the June 15, 2009 issue of CANCER, a peer-reviewed journal of the American Cancer Society.
Genetic marker may predict early onset of prostate cancer – Fox Chase Cancer Center researchers have identified a genetic marker that is associated with an earlier onset of prostate cancer in Caucasian men who have a family history of prostate cancer. If the data are confirmed, the marker may help clinicians personalize prostate cancer screening.
Triple drug combination is promising option to treat metastatic HER2+ breast cancer – Combining two chemotherapy drugs with trastuzumab (Herceptin) to treat women who have metastatic HER2+ breast cancer may offer physicians another choice in their treatment options.
GenWay Biotech obtains exclusive rights to AMDL’s DR-70 cancer test in US and Canada. AMDL Inc. executes two exclusive distribution agreements for cancer test with GenWay Biotech Inc. – GenWay Biotech, Inc., a US-based diagnostic company which specializes in providing protein and antibody solutions, announced its partnership with AMDL, Inc., a US-based pharmaceutical company with major operations in China, regarding the distribution of AMDL’s DR-70 (FDP) cancer test in both the United States and Canada.
